Investigational drug · Phase 3
QLG2128
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Postmenopausal Women With Osteoporosis.
Phase 3Last checked: Nov 19, 2026Latest source record: Mar 27, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "QLG2128"
First trial start
2025
Jun 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "QLG2128", any sponsor or status.
Conditions studied
As listed on its trial records.
- Postmenopausal Women With Osteoporosis
Approved drugs for the same conditions: Osteoporosis · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "QLG2128" as an intervention, largest first.
- To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of FracturePivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT06898060 · 282 participants (planned) · Start Jun 2025 · Primary completion May 2027
Drug: QLG2128; Teriparatide Injection · For: Postmenopausal Women With Osteoporosis
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Postmenopausal Women With Osteoporosis
- SAL056Phase 21 trial
Shenzhen Salubris Pharmaceuticals Co., Ltd. · Postmenopausal Women With Osteoporosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.